San Diego-dependent Viking Therapeutics marked by itself as a serious competitor within the weight loss drug industry in February right after revealing promising data from the mid-phase demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when offered like a weekly injection and in March the company